clinical trials, drug development, cancer

Scientists incorporate genetic analyses to streamline and accelerate clinical trials

An unfolded protein found in human milk shows promise in early clinical trials to treat bladder cancer.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 

A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

Protesters crash the BIO conference to protest the delayed approval of a breast cancer drug.

The regulatory agency will allow early-stage breast cancer patients to try experimental drugs previously reserved for those with advanced disease.

Over the past 15 years, new laws and regulations in the United States and the European Union have expanded to require the inclusion of pediatric patients in clinical drug trials.  

Dwindling stocks in more than a dozen cancer drugs are delaying clinical trials.

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.